XenTech scientist to present new pediatric liver cancer models at WIN 2014


XenTech scientist to present new pediatric liver cancer models at WIN 2014


XenTech Logo

Press Release | XenTech

JUNE 16, 2014

Evry, France: – Dr. Stefano Cairo, a leading scientist with biotech and contract research organisation XenTech, will be presenting details on pioneering new preclinical Pediatric Liver Cancer models at this month’s WIN 2014 Symposium in Paris.

Dr. Cairo and his team at XenTech developed the first panel of patient-derived tumor xenograft (PDX) models representing rare pediatric liver cancers after several years’ research. The models are now ready for therapeutic screening and preclinical trials based on in vivo drug efficacy assays and biomarker discovery.

“I look forward to discussing potential use of what we believe will be an Innovative and versatile tool contributing to improved understanding of pediatric tumors with peers at WIN 2014,” said Dr. Cairo.

Unique pediatric models

The new XenTech PDX panel presents both unique preclinical models of pediatric cancer but also new models that can be used for the evaluation of therapies targeting Wnt pathway-dependent cancers.

“The new panel will also form a new service offer from XenTech that we believe will be of great value to pharmaceutical and biotech companies conducting oncological research,” Dr. Cairo added.

Dr., Stefano Cairo has worked at XenTech at Evry, near Paris, since December 2009. He leads the XenTech R&D team seeking to identify genetic markers, pathways and signatures that can be used to predict tumor response to conventional or innovative anti-cancer treatment.

After gaining his Ph.D. in human genetics in 2004 from Telethon Institute of Genetics and Medicine (TIGEM) in Naples, Italy, Dr. Cairo then studied liver disease and cancer, specifically hepatoblastoma, in the laboratory of Dr. Marie Annick Buendia at Institut Pasteur in Paris.

Dr. Cairo has published several high-impact, sentinel scientific papers leading to new insights into what causes and drives hepatoblastoma.

About XenTech

XenTech is an innovative biotech laboratory and CRO specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX), which closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.

XenTech has assembled one of the world’s most impressive collections of breast cancer PDX models that are extensively characterized by and associated with molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value to translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine.

XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.

XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts, the quality of its services and it’s extremely experienced scientific team.

About WIN 2014

The annual WIN Symposium is a global event dedicated to breakthrough biomarker investigations and combination therapies for cancer.

The symposium is hosted by the Worldwide Innovative Networking (WIN) consortium, which is a pioneering, non-profit, global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, health plans, and patient advocacy groups.

The consortium unites these stakeholders in addressing the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of tumors and accounting for genetic differences across diverse populations. Headquartered in Paris, it was founded in 2010 as a join initiative by France’s Institut Gustave Roussy and The MD Anderson Cancer Center at University of Texas.

The 2014 symposium will be held at the Marriott Rive Gauche Hotel & Conference Center in Paris on June 23-24. The three plenary sessions will explore Molecular analysis of immune cells and immunotherapy, hemato-oncology and innovative therapeutic initiatives and models of cooperation.

Media Contact

Léa Carrignon, Business Development Manager, XenTech
Tel: +33 1 60 87 89 80
Email: lea.carrignon@xentech.eu

Resources

Click on XenTech scientist to present new pediatric liver cancer models at WIN 2014 for other information.
Click on
XenTech to contact the company directly.


Supplier Information
Supplier: Xentech
Address: 4, rue Pierre Fontaine, F 91000 Evry, France
Tel: +33 1 60 87 89 80
Fax: +33 1 60 87 89 62
Website: www.xentech.eu


Comments are closed.